From: A stepwise data interpretation process for renal amyloidosis typing by LMD-MS
Training set | Validation set | Non-amyloid nephropathy | ||||||
---|---|---|---|---|---|---|---|---|
DN | FGN | IgAN | LN | MN | NAT | |||
Age (years) | 60.0 (52.0–64.0) | 61.0 (51.8–67.3) | 56.0 (51.0–60.0) | 43.0 (39.0–46.8) | 41.0 (31.0–42.0) | 34.0 (29.0–38.0) | 51.0 (45.0–56.0) | - |
Gender (male/female) | 22/20 | 31/19 | 6/7 | 2/6 | 3/6 | 0/5 | 12/3 | 5a |
Upro (mg/day) | 3482 (1731–7490) | 3716 (2755–5687) | 3835 (2658–8013) | 3480 (2740–5340) | 1060 (815–1690) | 3583 (2142–6214) | 3984 (3720–4248) | - |
Alb (g/L) | 22.9 (17.8–28.3) | 25.7 (20.7–29.3) | 27.4 (25.1–32.2) | 31.8 (28.9–33.4) | 38.8 (38.7–39.0) | 26.2 (24.0–29.7) | 16.8 (15.8–17.7) | - |
Scr (μmol/L) | 84.0 (58.0–141.0) | 85.0 (68.5–100.0) | 108.0 (60.0–191.0) | 64.0 (57.0–99.0) | 82.0 (67.0–92.0) | 64.0 (59.0–68.0) | 93 (85.5–100.5) | - |
BUN (mmol/L) | 6.0 (5.4–9.0) | 7.3 (4.5–9.2) | 5.4 (4.4–7.7) | 4.7 (3.3–6.2) | 5.6 (5.2–7.0) | 5.4 (3.6–5.5) | 5.0 (3.4–5.8) | - |